Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate-to-severe atopic dermatitis

Available online 10 April 2024

The Journal of Allergy and Clinical Immunology: In Practice

Author links open overlay panel, , , , , KEY WORDS

atopic dermatitis

baricitinib

biomarker

dupilumab

efficacy

real-world

Th2

Th1

transcriptome

© 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

View original article

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

0 0 0 0 0 0 0

Comments (0)